Ann: 1H FY23 Results Presentation, page-68

No guidance, but Swami mentioned growth trajectory should be maintained and is hopeful of "exponential" growth in several markets

from memory:

DW said that the hoped to be market leaders in western Europe and the UK/Ireland within 12 to 18months, they are getting real traction. UK sales are expected to be bigger than Australia within that time frame.
The diabetic foot ulcer trial has been temporarily halted because they have discovered results are sensitive to the technique. To get the best results they need to tweak the protocol and train people to follow it closely. Once the protocol has been optimised the trial will be restarted.
No sales in India yet because they don't have the proper commercial sales certificates. But they have identified a 20 strong sales team and it's all ready to go, hopefully within a few weeks.
They are making contributions to Ukrainian war wounded through the channels that they have available.
Hernia and Breast devices still being worked on but don't expect much in the short term
DW says their penetration in the market is still early but they are building a good reputation with end users and growth is excellent. They are adjusting their sales team strategy to improve productivity in the US.
The BARDA trial will hopefully be extended to India and Canada with results mid 2025
DW is not interested in wasting cash on dividends. Stellar revenue growth will drive the share price so people can sell a few shares to raise cash if they wish. The BoD won't sacrifice growth to declare a trivial dividend.